CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 92 enrolled
Drug / intervention
Methotrexatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02074319
NCT02074319Phase 1Completed
CompareCT.gov

A Randomised Double Blind Placebo Controlled 12 Week Trial of Methotrexate Added to Treatment As Usual in Early Schizophrenia

Pakistan Institute of Living and Learning·interventional·Posted Feb 28, 2014·Updated Sep 22, 2015

In Brief

A Phase 1 clinical trial evaluating Methotrexate for Schizophrenia and 2 related conditions. Completed, enrolled 92 participants across 4 sites.

Detailed Summary

The aim of the this study is to evaluate the effectiveness of methotrexate added to treatment as usual on positive and negative symptoms, cognitive and social functioning and quality of life of patients suffering from schizophrenia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
CountriesPakistan
CollaboratorsAbbasi Shaheed Hospital, Dow University of Health Sciences, Karwan e Hayat, Karachi, Pakistan, Institute of Behavioural Sciences, Karachi, Pakistan

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 28, 2014
Enrollment StartDec 1, 2013
Primary CompletionJul 1, 2015
Study CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 12.3 years ago

Interventions

Methotrexatedrug

Treatment as usual or standard treatment for psychosis will be common in all arms